Â鶹ֱ²¥ & Lardner LLP acted as intellectual property counsel for Zetagen Therapeutics, Inc. and assisted the company in nearly doubling its worldwide IP portfolio to 64 patents, spanning across 36 countries including the United States, Europe, Canada, Australia, Japan, United Kingdom, India, Sweden, and Switzerland. The technologies patented by Zetagen in 2024 contain landmark science, including new chemicals and describing novel chemistries and formulations of the company’s proprietary drug-carrier platform.
Zetagen is a private, clinical stage, biopharmaceutical company focused on developing proprietary carriers delivering tumoricidal therapies for metastatic and primary breast cancer, which may minimize patient side effects with the potential to increase survival rates. The latest patent awards are for new molecular pathways, proprietary carriers, and optimum dose ranges to treat breast cancer and included multiple submissions of Composition of Matter for new molecular entities issued from the U.S. Patent and Trademark Office.
The Â鶹ֱ²¥ team was led by partner Stephen Maebius and included associate Rebecca Kimmelfield, senior patent agent Alexey Saprigin, and patent agent Rachel Utterback Peters.
